GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rigel Pharmaceuticals Inc (STU:RI2A) » Definitions » 3-Year EPS without NRI Growth Rate

Rigel Pharmaceuticals (STU:RI2A) 3-Year EPS without NRI Growth Rate : 8.00% (As of Mar. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Rigel Pharmaceuticals 3-Year EPS without NRI Growth Rate?

Rigel Pharmaceuticals's EPS without NRI for the three months ended in Mar. 2024 was €-0.05.

During the past 3 years, the average EPS without NRI Growth Rate was 8.00% per year. During the past 5 years, the average EPS without NRI Growth Rate was 18.10% per year. During the past 10 years, the average EPS without NRI Growth Rate was 18.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Rigel Pharmaceuticals was 68.60% per year. The lowest was -21.40% per year. And the median was 17.15% per year.


Competitive Comparison of Rigel Pharmaceuticals's 3-Year EPS without NRI Growth Rate

For the Biotechnology subindustry, Rigel Pharmaceuticals's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rigel Pharmaceuticals's 3-Year EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rigel Pharmaceuticals's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Rigel Pharmaceuticals's 3-Year EPS without NRI Growth Rate falls into.



Rigel Pharmaceuticals 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


Rigel Pharmaceuticals  (STU:RI2A) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


Rigel Pharmaceuticals 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Rigel Pharmaceuticals's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Rigel Pharmaceuticals (STU:RI2A) Business Description

Industry
Traded in Other Exchanges
Address
611 Gateway Boulevard, Suite 900, South San Francisco, CA, USA, 94080
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility to develop and market the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

Rigel Pharmaceuticals (STU:RI2A) Headlines

No Headlines